Skip to content

Clinical Sample Validation of Molecular Markers Associated With Pancreatitis-Induced Lung Injury

Clinical Sample Validation of Molecular Markers Associated With Pancreatitis-Induced Lung Injury

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119361
Enrollment
Unknown
Registered
2026-02-26
Start date
2026-02-26
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis, pancreatitis-associated acute lung injury

Interventions

Acute pancreatitis group:NA
Pancreatitis-associated lung injury group:NA
Healthy control cohort:NA

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Inclusion criteria for the acute pancreatitis-associated lung injury group: Age between 18 and 80 years old; Patients diagnosed with pancreatitis-associated lung injury. 2.Inclusion Criteria for the Pancreatitis Group Aged 18 to 80 years old; Patients diagnosed with pancreatitis. 3.Inclusion Criteria for the Healthy Population Group Aged 18 to 80 years old.

Exclusion criteria

Exclusion criteria: 1.Exclusion Criteria for Patients with Pancreatitis-associated Lung Injury: Patients with chronic pancreatitis or pancreatic cancer; Patients with severe organic diseases, such as malignant tumor, acute myocardial infarction, extensive cerebral infarction, etc.; Pregnant or lactating women. 2.Exclusion Criteria for Pancreatitis Patients: Patients with chronic pancreatitis or pancreatic cancer; Patients with severe organic diseases, such as malignant tumor, acute myocardial infarction, extensive cerebral infarction, etc.; Pregnant or lactating women. 3.Exclusion Criteria for Healthy Individuals: Presence of pancreatic diseases such as acute pancreatitis, chronic pancreatitis, or pancreatic cancer; Suffering from severe organic diseases, such as malignant tumors, acute myocardial infarction, extensive cerebral infarction, etc.; History of systemic treatment (such as surgery, radiotherapy, chemotherapy, targeted therapy, etc.); Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Expression of molecules related to pancreatitis-associated lung injury;

Countries

China

Contacts

Public ContactQingping Wen

The First Affiliated Hospital of Dalian Medical University

wqp.89@163.com+86 411 8363 5972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026